Venetoclax penetrates in cerebrospinal fluid and may be effective in CLL with central nervous system involvement.

Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy.[1][1] Central nervous system involvement (CNSi) is a rare complication of CLL[2][2],[3][3] and is reported in approximately 0.4% of patients.[